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Background: The preoperative diagnosis of thyroid follicular carcinomas by fine-90 
needle aspiration cytology (FNAC) is almost impossible. We previously demonstrated 91 
that p53-binding protein 1 (53BP1) expression, based on immunofluorescence (IF), can 92 
serve as a valuable biomarker to estimate the malignant potential of various cancers. 93 
53BP1 belongs to a class of DNA damage response molecules that rapidly localize to 94 
the site of DNA double-strand breaks (DSBs), forming nuclear foci (NF). This study 95 
aimed to elucidate the utility of 53BP1 NF expression as a biomarker to differentiate 96 
follicular tumors (FTs). 97 
Methods: We analyzed associations between 53BP1 expression based on IF and 98 
histological types of FTs using 27 follicular adenomas (FAs), 28 minimally invasive 99 
follicular carcinomas (MFCs), and 14 widely invasive FCs (WFCs). Furthermore, our 100 
study clarified the relationship between 53BP1 NF and copy number aberrations 101 
(CNAs) based on array comparative genomic hybridization (aCGH), a hallmark of 102 
genomic instability (GIN). 103 
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Results: This study demonstrated differences in 53BP1 NF expression between FA and 104 
FC. The incidence of 53BP1 at NF significantly increased with FT progression in the 105 
following order: normal follicle < FA < MFC < WFC. In contrast, no significant 106 
differences were observed in CNAs among the FT samples. Furthermore, there was no 107 
significant correlation between CNAs and 53BP1 at NF in FTs. Thus, based on a 108 
comparison of these two indicators of GIN, 53BP1 NF (by IF) was better able to 109 
estimate the malignancy of FTs compared to CNA (by aCGH). Interestingly, IF 110 
revealed the heterogenous distribution of 53BP1 NF, which occurred more frequently in 111 
the invasive or subcapsular area than in the center of the tumor, suggesting intra-tumor 112 
heterogeneity of GIN in FTs. 113 
Conclusions: We propose that IF analysis of 53BP1 expression could be a novel 114 
diagnostic method to estimate the malignant potential of FTs. Because 53BP1 NF 115 
reflect DNA DSBs, we hypothesize that the incidence of 53BP1 at NF can represent the 116 





  Follicular carcinoma (FC) is the second most common type of thyroid carcinoma 120 
and must be differentiated from more common follicular adenoma (FA) (1). It is almost 121 
impossible to preoperatively diagnose thyroid follicular tumors (FTs) by fine-needle 122 
aspiration cytology (FNAC), because the criteria for distinguishing these lesions are 123 
based on histological evidence such as capsular/vascular invasion or metastasis, and not 124 
on cytologic features, as is the case for papillary thyroid carcinoma (PTC) (2,3). 125 
According to the Bethesda System for Reporting Thyroid Cytology, almost all FCs are 126 
of category III, which is defined as atypia of undetermined significance or follicular 127 
lesions of undetermined significance (AUS/FLUS), or category IV, which is defined as 128 
follicular neoplasm or suspicious for follicular neoplasm (FN/SFN); for these 129 
categories, the estimated risk of malignancy is 5–15% or 15–30%, respectively (4). 130 
Thus, to avoid unnecessary surgery, several patients with FC, especially those cases 131 
including vascular invasion, are required to undergo a complementary total 132 
thyroidectomy after a preceding histological diagnostic hemithyroidectomy. 133 
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Several molecular techniques have been proposed for the preoperative diagnosis of 134 
FTs (5-7), but there is no decisive method that can clearly distinguish benign tumors 135 
from malignancy. We previously demonstrated that an immunofluorescence (IF)-based 136 
method to detect p53-binding protein 1 (53BP1) expression can serve as a valuable 137 
molecular marker to estimate the malignant potential of various cancers including 138 
thyroid (8), skin (9), and uterine cervix (10). 53BP1 belongs to a family of 139 
evolutionarily conserved DNA damage response (DDR) molecules that are rapidly 140 
recruited to the site of DNA double-strand breaks (DSBs) as a downstream effector of γ-141 
H2AX (11); these molecules then form nuclear foci (NF) to co-operatively activate p53 142 
with other kinases (12-14). The recruitment of 53BP1 protects the damaged end of 143 
DNA from undergoing resection, which in turn prevents error-free homologous 144 
recombination (HR) repair and instead promotes error-prone non-homologous end-145 
joining (NHEJ) (15-19). The expression of 53BP1 at NF has been found to reflect 146 
ionizing radiation-induced DSBs, which increase linearly with radiation dose (12). 147 
Genomic instability (GIN) is considered an important hallmark of malignant tumors and 148 
is occasionally evident in the precancerous stage of carcinogenesis. Given that one 149 
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manifestation of GIN is induction of the endogenous DDR (20), we proposed that 150 
53BP1 NF, based on IF, might be a useful tool to estimate the level of GIN, as well as 151 
the malignant potential of human tumors. 152 
To elucidate the utility of 53BP1 expression as a biomarker to differentiate thyroid 153 
FTs, this study analyzed associations between 53BP1 expression and histological types 154 
such as FAs, minimally invasive FCs (MFCs), and widely invasive FCs (WFCs). 155 
Furthermore, to validate the significance of 53BP1 NF in estimating GIN among FTs, 156 
our study also clarified the relationship between 53BP1 NF and copy number 157 
aberrations (CNAs) detected by array comparative genomic hybridization (aCGH), 158 
which is a well-known hallmark of GIN during carcinogenesis (13, 14). 159 
 160 
Materials and Methods 161 
Thyroid tissues 162 
A total of 69 surgically-resected, formalin-fixed, paraffin-embedded (FFPE) 163 
thyroid FTs including 27 conventional-type FAs, 28 MFCs, and 14 WFCs were used in 164 
this study. The diagnoses of all patients were histologically and macroscopically 165 
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confirmed by a pathologist specializing in thyroid oncology (MH or MN). Any 166 
suspicious cases were excluded from our analysis. As a normal control, seven non-167 
tumorous follicular tissues surrounding FTs were also evaluated. Clinicopathologic 168 
factors and preoperative cytological diagnoses of these cases are summarized in Table 169 
1. This study was retrospectively conducted in accordance with the tenets of the 170 
Declaration of Helsinki and approved by the institutional ethical committee for medical 171 
research at Nagasaki University (approval date: July 24, 2015; #1506265). Following 172 
the guidelines of the ethical committee’s official informed consent and disclosure 173 
system, detailed information regarding the study is available on our website 174 
(http://www-sdc.med.nagasaki-u.ac.jp/pathology/research/index.html). Patients were 175 
able to opt out of the study by following the instructions on the faculty website. All 176 
samples were resected from patients at the Nagasaki University Hospital from 1994 to 177 
2012 and the Kuma Hospital from 2010 to 2012. 178 
 179 
IF analysis of 53BP1 expression 180 
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After antigen retrieval by microwaving in citrate buffer, deparaffinized 4-μm 181 
sections were preincubated with 10% normal goat serum. Tissue sections were then 182 
incubated with an anti-53BP1 rabbit polyclonal antibody (A300-272A, Bethyl Labs, 183 
Montgomery, TX) at a 1:200 dilution for 1 h at room temperature. The slides were 184 
subsequently incubated with Alexa Fluor 488-conjugated goat anti-rabbit antibody 185 
(Molecular Probes Inc., Eugene, OR, USA). Specimens were counterstained with 4′,6-186 
diamidino-2-phenylindole dihydrochloride (DAPI; Vysis Inc., Downers Grove, IL, 187 
USA), analyzed, and photographed using a High Standard All-in-One Fluorescence 188 
Microscope (Biorevo BZ-9000; KEYENCE Japan, Osaka, Japan) in Z-stack mode, 189 
accumulating images from 20 to 30 slices. Signals were analyzed from more than 15 190 
viewing areas of subcapsular parts per case at a 1,000-fold magnification, as shown in 191 
Figure 1A. The 53BP1 immunoreactivity pattern was classified into three types based 192 
on the number and size of NF as follows: (i) stable type: faint nuclear staining, (ii) low 193 
DDR type: one or two discrete NF, (iii) high DDR type: three or more discrete NF, or 194 
discrete NF that are larger than 1.0 μm in the minor axis (Fig. 1B). The percentage of 195 
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follicular cells expressing each type of 53BP1 staining pattern was calculated for each 196 
case. 197 
 198 
Validation of IF analysis of 53BP1 expression using FFPE tissues 199 
We also performed IF analysis of 53BP1 expression to determine whether 53BP1 200 
NF can be specifically detected in FFPE sections using thyroid tissues after irradiation. 201 
Seven-week-old male Wistar rats were used for this. All animals received whole-body 202 
irradiation using a Toshiba ISOVOLT TITAN32 X-ray, at 200 kV and a dose rate of 203 
0.5531 Gy/min. Two doses of 0.1 and 4 Gy were administered. Two rats in each dose 204 
group were sacrificed by deep anesthesia 2 h after irradiation. Each thyroid gland was 205 
resected and immersed in neutral-buffered formalin, and routinely embedded in paraffin 206 
blocks. Sections were used for IF according to the method described previously herein. 207 
Control rats were not irradiated but were otherwise handled identically. This 208 
experimental protocol was approved by the Institutional Animal Care and Use 209 




DNA extraction 212 
Genomic DNA was extracted from tumor areas in FFPE tissues as reported 213 
previously (21). Tumor areas, identified using a guide slide stained with hematoxylin 214 
and eosin, were microdissected from each FFPE block using 10 × 10-μm-thick-sections 215 
and transferred into tubes. Paraffin removal was performed in 80% xylene; then, tissues 216 
were washed twice with absolute ethanol and deparaffinized tissue pieces were 217 
centrifuged at 15,000 × g for 10 min at room temperature. After drying, pellets were 218 
resuspended in 180 μl of buffer ATL (QIAamp DNA FFPE Kit, Qiagen, Hilden, 219 
Germany) and digested with proteinase K for 72 h at 56 °C in a rotation oven with 220 
periodic mixing and the addition of fresh proteinase K every 24 h. DNA was collected 221 
using the QIAamp DNA FFPE Kit according to the manufacturer’s instructions. 222 
Extracted DNA was quantified using a NanoDrop ND-1000 spectrophotometer 223 
(NanoDrop Technologies, Wilmington, DE, USA). The concentration of double-224 
stranded DNA (dsDNA) in each sample was quantitated using a Qubit dsDNA HS 225 
Assay Kit (Life Technologies, Carlsbad, CA, USA), following the manufacturer’s 226 




aCGH analysis 229 
aCGH analyses were performed as described previously (15). The Genomic DNA 230 
ULS Labeling Kit (Agilent technologies, Santa Clara, CA, USA) was used to 231 
chemically label 500 ng of DNA from tumor samples and reference female genomic 232 
DNA (Promega, Madison, WI, USA) with Cy5 or Cy3 dyes, respectively, for 30 min at 233 
85 °C, which was followed by purification using Agilent-KREApure™ columns. The 234 
degrees of Cy5 and Cy3 labeling were calculated using a NanoDrop ND-2000 235 
spectrophotometer (NanoDrop Technologies). Purified, labeled samples were then 236 
combined and mixed with human Cot-1 DNA (Invitrogen, Carlsbad, USA), Agilent 10× 237 
Blocking Agent, and Agilent 2× Hybridization Solution. Prior to array hybridization, 238 
hybridization mixtures were denatured at 95 °C for 3 min and incubated at 37 °C for 30 239 
min. An Agilent CGH block was added, and samples were hybridized to the SurePrint 240 
G3 Human CGH 8×60 K Microarray, which contains eight identical arrays consisting of 241 
~63,000 in situ synthesized 60-mer oligonucleotide probes that span coding and 242 
noncoding sequences with an average spatial resolution of ~54 kb. Hybridization was 243 
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carried out at 65 °C for 40 h before washing in Agilent Oligo aCGH Wash Buffer 1 at 244 
room temperature for 5 min; this was followed by washing in Agilent Oligo aCGH 245 
Wash Buffer 2 at 37 °C for 1 min. Scanning and image analysis were performed using 246 
an Agilent DNA Microarray Scanner. Feature Extraction Software (version 9.5) was 247 
used for data extraction from raw microarray image files. The Agilent Genomic 248 
Workbench (version 6.5) was used to visualize, detect, and analyze chromosomal 249 
patterns using an Aberration Detection Method-2 algorithm with the threshold set to 250 
5.5. The derivative log ratio spread (DLRSpread) of each sample, which estimates the 251 
log ratio of noise by calculating the spread of log ratio differences between consecutive 252 
probes along all chromosomes, was used as an indicator of quality for aCGH analysis. 253 
A copy number gain was defined as a log2 ratio > 0.30 and a copy number loss was 254 
defined as a log2 ratio < −0.30. 255 
 256 
Statistical analysis 257 
Kruskal-Wallis or Cochran-Armitage tests were used to assess clinicopathologic 258 
factors of patients in this study. The Jonckheere-Terpstra test was used to assess 259 
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associations between the histological type of FTs (WFC, MFC, FA) and the results of 260 
preoperative cytology, and to assess differences in the level of 53BP1 expression or the 261 
total length of CNA by aCGH and the histological type of FTs. Spearman’s correlation 262 
coefficients based on rank tests were used to assess the correlation between 53BP1 263 
expression and the total length of CNA by aCGH. The PHREG procedure in SAS 264 
software (version 8.2; SAS Institute, Cary, NC, USA) was used for calculations. All 265 
tests were one-tailed, and a p-value < 0.05 was considered statistically significant. 266 
 267 
Results 268 
53BP1 expression in thyroid FTs 269 
Representative images of the staining pattern of 53BP1 expression based on IF are 270 
shown in Figure 2. Our IF analysis of 53BP1 expression revealed the heterogeneous 271 
distribution of 53BP1 NF in FT sections. Specifically, we found more frequent 272 
expression of 53BP1 NF in the invasive front or subcapsular area as compared to that in 273 
the center portion of FTs, which were defined as shown in Figure 1. Therefore, 53BP1 274 
expression was clarified at the site of the subcapsular areas of FTs. Based on these 275 
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results, we found a significant difference in the number of 53BP1 NF among different 276 
histological types of FTs. Representative images of IF analysis of 53BP1 expression in 277 
each FT histological type are presented in Figure 3. The median incidences of follicular 278 
cells expressing 53BP1 NF were 6.9, 20.9, 28.3, and 36.4% in non-tumor follicles 279 
(NTFs), FAs, MFCs, and WFCs, respectively. Furthermore, the median incidences of 280 
follicular cells expressing the high DDR type were 0, 4.3, 6.4, and 9.9% in NTFs, FAs, 281 
MFCs, and WFCs, respectively. Statistical analysis revealed a significant association 282 
between 53BP1 NF/high DDR type and the histological type of FTs (P < 0.001, Fig. 4 283 
and 5, respectively). The incidence of 53BP1 NF and high DDR type was significantly 284 
increased with disease progression, in the following order NTFs, FAs, MFCs, and 285 
WFCs. Adopting 3.1% as a cut-off value to distinguish FC from FA, the sensitivity and 286 
specificity values were 90.5 and 77.8%, respectively (Fig. 5). 287 
 288 




As shown in Figure 6, our IF method for assessing 53BP1 expression clearly 291 
demonstrated NF in rat thyroid follicular cells after irradiation. No 53BP1 NF were 292 
found in non-irradiated rat thyroid glands, whereas the number of NF per cell was 293 
increased in dose-dependent manner, suggesting the specific detection of 53BP1 NF at 294 
sites of irradiation-induced DSBs in FFPE sections.  295 
 296 
Correlation between type of 53BP1 expression and CNA by aCGH  297 
We further examined the correlation between the type of 53BP1 expression and 298 
CNA as another hallmark of GIN. The degree of CNA was measured by aCGH in FFPE 299 
samples that met the DNA quality standard for this assessment, which included eight 300 
FAs, 10 MFCs, and nine WFCs in our series. The quality of aCGH data was considered 301 
acceptable, with a DLRSpread of 0.38 (0.20–0.69). The mean total numbers of CNAs 302 
were 25.7, 32.2, and 120.8 Mbp in FAs, MFCs, and WFCs, respectively, which was not 303 
significantly different based on FT histologic type (p = 0.656; Fig. 7). Furthermore, the 304 
correlation diagram comparing total number of CNAs and the proportion of tumor cells 305 
expressing 53BP1 NF is shown in Figure 8. Our statistical analysis of Spearman’s 306 
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correlation coefficients based on the rank test revealed no significant correlation 307 
between the degree of CNA and 53BP1 NF or the high DDR type in FTs (p = 0.226 and 308 
0.779, respectively). According to CNA at the single chromosome level, our results 309 
identified gain of 19p13.2 in four (50%) of eight FAs and gain of 8q24.3 in three of 310 
eight FAs (37.5%), six (60%) of 10 MFCs, and four (44%) of nine WFCs. However, 311 




The present study clearly demonstrated the existence of differences in 53BP1 316 
expression at NF, particularly with respect to the incidence of tumor cells expressing the 317 
high DDR type, between FA and FC. The prevalence of the high DDR-type of 53BP1 318 
immunoreactivity in follicular cells appeared to increase with FT progression. As 319 
evident in a validation experiment using irradiated rat thyroid glands, the presence of 320 
NF or DDR-type 53BP1 immunoreactivity was found to be concordant with the 321 
induction of DNA DSBs in follicular cells. Furthermore, our supplementary experiment 322 
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based on double IF analysis revealed the frequent co-localization of 53BP1 and γH2AX 323 
NF in all examined FTs (10 cases), as well as in irradiated rat thyroid glands, suggesting 324 
that endogenous activation of the DDR in tumor cells is a hallmark of GIN 325 
(Supplementary figure). These results indicate a higher level of GIN in FCs as 326 
compared to that in FAs. However, although CNAs (based on aCGH analysis), as 327 
another hallmark of GIN and representing chromosomal loss and gain (13, 14, 21-23), 328 
tended increase with FT progression, no significant difference was observed among FA, 329 
MFC, and WFC samples. Previous reports also suggested no significant differences in 330 
CNAs between FC and FA (24, 25). Furthermore, we could not demonstrate a 331 
significant correlation between CNA levels and the DDR-type of 53BP1 332 
immunoreactivity in FTs. Thus, upon comparing these two indicators of GIN, the 333 
incidence of 53BP1 NF, reflecting endogenous DNA DSBs, based on IF, could be more 334 
accurate in estimating the malignant potential of FTs, as compared to that with can-335 
based aCGH analysis. Interestingly, our IF analysis revealed the heterogenous 336 
distribution of 53BP1 NF, which was more frequent in the invasive front or subcapsular 337 
area, as compared to that in the center of the tumor, suggesting intra-tumor 338 
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heterogeneity of GIN in FTs. Thus, the intra-tumor heterogeneity based on CNA levels 339 
should be further elucidated. Actually, a previous study suggested the presence of tumor 340 
heterogeneity in FC based on aCGH (26).  341 
According to the 2017 Bethesda System for Reporting Thyroid Cytology, in the 342 
cases of category III or IV, molecular testing is recommended to obtain further 343 
diagnostic information as usual management. Several molecular techniques were 344 
reportedly proposed for the preoperative diagnosis of FTs (5-7), but there is no critical 345 
method that can clearly distinguish between benign tumors and malignancy. Although 346 
there are several publications analyzing differences in CNAs among FTs by aCGH (25-347 
32), to the best of our knowledge, any specific features that can distinguish FA or FC, 348 
which have been practically utilized, have not yet been identified. It has been reported 349 
that the gene-expression classifier Afirma® Thyroid FNA Analysis is practically 350 
available for the preoperative risk assessment of thyroid nodules with indeterminate 351 
FNAC (33). This diagnostic test is based on a microarray gene-expression assay 352 
measuring the expression of 167 genes using FNAC samples and was found to correctly 353 
identify 78 of 85 nodules as suspicious for malignancy (92% sensitivity), with a 354 
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specificity of 52% among 265 cytologically-indeterminate nodules (33). For nodules 355 
classified as FN/SFN, the sensitivity was 90% and the specificity was 49%, suggesting 356 
difficulties associated with predicting benign FT correctly using this assay (33). More 357 
recently, the next-generation sequencing (NGS)-based ThyroSeq® using FNAC 358 
samples was also made available (34). The ThyroSeq v2.1 panel detects known thyroid 359 
cancer-associated molecular alterations including 14 genetic point mutations and 42 360 
types of fusion genes (34). By analyzing 462 AUS/FLUS nodules of thyroid follicular 361 
cells, this test revealed 31 (6.7%) were positive for mutations. Among them, 26 (84%) 362 
were surgically removed and 20 (77%) malignant and six (23%) benign lesions were 363 
histologically confirmed. Based on the results, all 20 malignant nodules were PC 364 
including 18 follicular variants. The authors finally concluded that ThyroSeq v2.1 was 365 
able to classify 20 of 22 cancers correctly, showing a sensitivity of 90.9%, a specificity 366 
of 92.1%, a positive predictive value of 76.9%, and a negative predictive value of 367 
97.2%, with an overall accuracy of 91.8%. Thus, although the accuracy of molecular 368 
assays using FNAC samples has recently improved, it is still difficult to correctly 369 
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predict FCs of Bethesda category III (AUS/FLUS) or IV (FN/SFN), even by using 370 
modern techniques, and thus these methodologies require further improvements.  371 
In summary, this retrospective study suggests that the incidence of high DDR-type 372 
53BP1 immunoreactivity in FTs could be an attractive candidate biomarker to 373 
distinguish FC from FA. Indeed, when we adopted 3.1% as a cut-off value for the 374 
incidence of high DDR-type, this test could differentiate FC or FA among 69 FFPE FT 375 
samples with a sensitivity of 90.5% and a specificity of 77.8%. Although it is limited by 376 
the lower specificity, which means that a significant fraction of FA is not 377 
distinguishable, we propose that IF analysis of 53BP1 expression could represent a 378 
novel diagnostic method to estimate the malignant potential of thyroid FTs based on 379 
post-operative FFPE samples. Because 53BP1 NF reflect spontaneously occurring DNA 380 
DSBs, we hypothesize that the incidence of these foci can represent the level of GIN in 381 
tumor cells. IF analysis is associated with much lower cost and is technically easier 382 
compared to microarray gene-expression assays or NGS assays; it can also be used with 383 
both FFPE and FNAC samples. Thus, IF analysis of 53BP1 expression will not only be 384 
an auxiliary histologic technique to accurately diagnose FTs but also a novel technique 385 
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to make preoperative diagnoses based on FNAC from the invasive front or subcapsular 386 
portion of FTs. Further studies using cytologic specimens are required to confirm this 387 
notion in the near future. 388 
 389 
Acknowledgements 390 
This work was supported in part through the Atomic Bomb Disease Institute, 391 
Nagasaki University, by a Grant-in-Aid for Scientific Research from the Japanese 392 
Ministry of Education, Science, Sports and Culture (No. 24590414, No. 26461951), and 393 
by the Program of the Network-Type Joint Usage/Research Center for Radiation 394 
Disaster Medical Science. 395 
 396 
Author Disclosure Statement 397 




1. Hemmer S, Wasenius VM, Knuutila S, Joensuu H, Franssila K 1998 Comparison of 400 
benign and malignant follicular thyroid tumours by comparative genomic 401 
hybridization. Br J Cancer 78:1012–1017. 402 
2. McHenry CR, Phitayakorn R 2011 Follicular adenoma and carcinoma of the 403 
thyroid gland. Oncologist 16:585–593. 404 
3. Suster S 2006 Thyroid tumors with a follicular growth pattern: problems in 405 
differential diagnosis. Arch Pathol Lab Med 130:984–988. 406 
4. Cibas ES, Ali SZ 2009 The Bethesda System for Reporting Thyroid Cytopathology. 407 
Thyroid 19:1159–1165. 408 
5. Sobrinho-Simões M, Preto A, Rocha AS, Castro P, Máximo V, Fonseca E, Soares P 409 
2005 Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 410 
447:787–793. 411 
6. Foukakis T, Gusnanto A, Au AY, Höög A, Lui WO, Larsson C, Wallin G, 412 
Zedenius J 2007 A PCR-based expression signature of malignancy in 413 
follicular thyroid tumors. Endocr Relat Cancer 14:381–391. 414 
 
 28
7. Nagar S, Ahmed S, Peeples C, Urban N, Boura J, Thibodeau B, Akervall J, Wilson 415 
G, Long G, Czako P 2014 Evaluation of genetic biomarker for distinguishing benign 416 
from malignant thyroid neoplasms. Am J Surg 207:596–601. 417 
8. Nakashima M, Suzuki K, Meirmanov S, Naruke Y, Matsuu-Matsuyama M, Shichijo 418 
K, Saenko V, Kondo H, Hayashi T, Ito M, Yamashita S, Sekine I 2008 Foci formation 419 
of p53-binding protein 1 in thyroid tumors: activation of genomic instability during 420 
thyroid carcinogenesis. Int J Cancer 122:1082–1088. 421 
9. Naruke Y, Nakashima M, Suzuki K, Matsuu-Matsuyama M, Shichijo K, Kondo H, 422 
Sekine I 2008 Alteration of p53-binding protein 1 expression during skin 423 
carcinogenesis: Association with genomic instability. Cancer Sci 99:946–951. 424 
10. Matusda K, Miura S, Kurashige T, Suzuki K, Kondo H, Ihara M, Nakajima H, 425 
Masuzaki H, Nakashima M 2011 Significance of p53-binding protein 1 nuclear foci 426 
in uterine cervical lesions: endogenous DNA double strand breaks and genomic 427 
instability during carcinogenesis. Histopathology 59:441–451. 428 
11. Wang B, Matsuoka S, Carpenter PB, Elledge SJ 2002 53BP1, a mediator of the DNA 429 
damage checkpoint. Science 298:1435–1438. 430 
 
 29
12. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD 2000 p53 binding protein 1 431 
(53BP1) is an early participant in the cellular response to DNA double-strand breaks. 432 
J Cell Biol 151:1381–1390. 433 
13. Negrini S, Gorgoulis VG, Halazonetis TD 2010 Genomic instability-an evolving 434 
hallmark of cancer. Nat Rev Mol Cell Biol 11:220–228. 435 
14. Mondello C, Smirnova A, Giulotto E 2008 Gene amplification, radiation sensitivity 436 
and DNA double-strand breaks. Mutat Res 704:29–37. 437 
15. Bunting SF, Callén E, Wong N, Chen H-T, Polato F, Gunn A, Bothmer A, Feldhahn 438 
N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, Nussenzweig M, Stark 439 
JM, Nussenzweig A 2010 53BP1 inhibits homologous recombination in Brca1-440 
deficient cells by blocking resection of DNA breaks. Cell 141: 243–254. 441 
16. Cao L, Xu X, Bunting SF, Liu J, Wang R-H, Cao LL, Wu JJ, Peng T-N, Chen J, 442 
Nussenzweig A, Deng CX, Finkel T 2009 A selective requirement for 53BP1 in the 443 
biological response to genomic instability induced by Brca1 deficiency. Mol Cell 35: 444 
534–541. 445 
17. Chapman JR, Taylor MR, Boulton SJ. Playing the end game 2012 DNA double-446 
 
 30
strand break repair pathway choice. Mol Cell 47:497–510. 447 
18. Kakarougkas A, Ismail A, Klement K, Goodarzi AA, Conrad S, Freire R, Shibata A, 448 
Lobrich M, Jeggo PA 2013 Opposing roles for 53BP1 during homologous 449 
recombination. Nucleic Acids Res 41:9719–9731. 450 
19. Zimmermann M, de Lange T 2014 53BP1: pro choice in DNA repair. Trends Cell 451 
Biol 24:108–117. 452 
20. Suzuki K, Yokoyama S, Waseda S, Kodama S, Watanabe M 2003 Delayed 453 
reactivation of p53 in the progeny of cells surviving ionizing radiation. Cancer Res 454 
63:936–941. 455 
21. Oikawa M, Yoshiura K, Kondo H, Miura S, Nagayasu T, Nakashima M 2011 456 
Significance of genomic instability in breast cancer in atomic bomb survivors: 457 
analysis of microarray-comparative genomic hybridization. Radiat Oncol 6:168. 458 
22. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D 459 
1994 Optimizing comparative genomic hybridization for analysis of DNA sequence 460 
copy number changes in solid tumors. Genes Chromosomes Cancer 10:231–243. 461 
 
 31
23. Mitelman F, Johansson B, Mertens F 2004 Fusion genes and rearranged genes as a 462 
linear function of chromosome aberrations in cancer. Nat Genet 36:331–334. 463 
24. Roque L, Rodrigues R, Pinto A, Moura-Nunes V, Soares J 2003 Chromosome 464 
imbalances in thyroid follicular neoplasms: a comparison between 465 
follicular adenomas and carcinomas. Genes Chromosomes Cancer 36:292–302. 466 
25. Qureshi AA, Collins VP, Jani P 2013 Genomic differences in benign and malignant 467 
follicular thyroid tumours using 1-Mb array-comparative genomic hybridisation. Eur 468 
Arch Otorhinolaryngol 270:325–335. 469 
26. Da Silva L, James D, Simpson PT, Walker D, Vargas AC, Jayanthan J, Lakhani 470 
SR, McNicol AM 2011 Tumor heterogeneity in a follicular carcinoma of thyroid: a 471 
study by comparative genomic hybridization. Endocr Pathol 22:103–107. 472 
27. Hemmer S, Wasenius VM, Knuutila S, Joensuu H, Franssila K 1998 Comparison of 473 
benign and malignant follicular thyroid tumours by comparative genomic 474 
hybridization. Br J Cancer 78:1012–1017. 475 
28. Hemmer S, Wasenius VM, Knuutila S, Franssila K, Joensuu H 1999 DNA copy 476 
number changes in thyroid carcinoma. Am J Pathol 154:1539–1547. 477 
 
 32
29. Frisk T, Kytölä S, Wallin G, Zedenius J, Larsson C 1999 Low frequency of 478 
numerical chromosomal aberrations in follicular thyroid tumors detected 479 
by comparative genomic hybridization. Genes Chromosomes Cancer 25:349–353. 480 
30. Roque L, Rodrigues R, Pinto A, Moura-Nunes V, Soares J 2003 Chromosome 481 
imbalances in thyroid follicular neoplasms: a comparison between 482 
follicular adenomas and carcinomas. Genes Chromosomes Cancer 36:292–302. 483 
31. Rodrigues RF, Roque L, Rosa-Santos J, Cid O, Soares J 2004 Chromosomal 484 
imbalances associated with anaplastic transformation of follicular thyroid 485 
carcinomas. Br J Cancer 90:492–496. 486 
32. Castro P, Eknaes M, Teixeira MR, Danielsen HE, Soares P, Lothe RA, Sobrinho-487 
Simões M 2005 Adenomas and follicular carcinomas of the thyroid display two 488 
major patterns of chromosomal changes. J Pathol 206:305–311. 489 
33. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, 490 
Friedman L, Kloos RT, LiVolsi VA, Mandel SJ, Raab SS, Rosai J, Steward DL, 491 
Walsh PS, Wilde JI, Zeiger MA, Lanman RB, Haugen BR 2012 Preoperative 492 
 
 33
diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 493 
367:705–715. 494 
34. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding 495 
WE, LeBeau SO, Ohori NP, Seethala RR, Tublin ME, Yip L, Nikiforova MN 2015 496 
Impact of the Multi-Gene ThyroSeq next-generation sequencing assay on cancer 497 
diagnosis in thyroid nodules with atypia of undetermined significance/follicular 498 




Figure legends 1 
Fig. 1. Definition of anatomic sites of follicular tumors (A) and types of p53-binding 2 
protein 1 (53BP1) immunoreactivity (B) in this study. (A) The subcapsule was defined 3 
as an area within 2 mm of the inner line of the capsule and the center comprised an area 4 
more than 2 mm from the inner line of the capsule of tumors. (B) NF: nuclear foci; 5 
DDR: DNA damage response. 6 
 7 
Fig. 2. Representative images of immunofluorescence analysis of p53-binding protein 1 8 
(53BP1) expression in a follicular tumor. The incidence of 53BP1 nuclear foci was 9 
higher with invasion and in subcapsular areas compared to that in the center of the 10 
tumor or non-tumor thyroid. 11 
 12 
Fig. 3. Immunofluorescence analysis of p53-binding protein 1 (53BP1) expression in 13 
follicular tumors of the thyroid. The incidence of 53BP1 nuclear foci in follicular cells 14 
was increasingly observed with follicular tumor progression based on the following 15 
order: normal follicle (A), adenoma (B), minimally invasive carcinoma (C), widely 16 
invasive carcinoma (D). 17 
 18 
Fig. 4. Comparison of median incidences of follicular cells expressing p53-binding 19 
protein 1 (53BP1) nuclear foci (NF) among follicular tumors (FTs) of the thyroid. The 20 
incidence of 53BP1 NF, which was measured in the subcapsular area of tumors, 21 
significantly (p < 0.001) increased in the order of follicular adenoma (FA), minimally 22 
invasive follicular carcinoma (MFC), and widely invasive follicular carcinoma (WFC). 23 
 24 
Fig. 5. Comparison of median incidences of follicular cells expressing the high DNA 25 
damage response (DDR)-type of p53-binding protein 1 (53BP1) among follicular 26 
tumors (FTs) of the thyroid. The incidence of high DDR-type 53BP1 expression, which 27 
was measured in the subcapsule areas of tumors, significantly (p < 0.001) increased in 28 
the order of follicular adenoma (FA), minimally invasive follicular carcinoma (MFC), 29 
and widely invasive follicular carcinoma (WFC). Upon adopting a 3.1% cut-off value 30 
for the incidence of the high DDR-type, this model could differentiate FC or FA among 31 
69 FT cases with a sensitivity of 90.5% and a specificity of 77.8%. 32 
 33 
Fig. 6. Immunofluorescence analysis of p53-binding protein 1 (53BP1) expression in 34 
irradiated rat thyroid tissues to detect DNA double strand breaks (DSBs) using 35 
formalin-fixed paraffin-embedded sections. No 53BP1 nuclear foci (NF) were observed 36 
in non-irradiated thyroid tissues, whereas the number of NF per cell was increased with 37 
irradiation in a dose-dependent manner. 38 
 39 
Fig. 7. Comparison of the mean total number of copy number aberrations (CNAs) by 40 
array comparative genomic hybridization among follicular tumors (FTs) of the thyroid. 41 
No significant differences in CNAs were observed among histologic types of FTs 42 
including follicular adenoma (FA), minimally invasive follicular carcinoma (MFC), and 43 
widely invasive follicular carcinoma (WFC) (p = 0.656).  44 
 45 
Fig. 8. Diagram of the correlation between total number of copy number aberrations 46 
(CNAs), based on array comparative genomic hybridization, and the incidence of tumor 47 
cells expressing p53-binding protein 1 (53BP1) nuclear foci (NF) in follicular tumors 48 
(FTs). No significant correlation between the number of CNAs and the expression of 49 
53BP1 NF or the high DNA damage response (DDR)-type was observed in FTs 50 
including follicular adenoma (FA), minimally invasive follicular carcinoma (MFC), and 51 
widely invasive follicular carcinoma (WFC) (p = 0.226 and 0.779, respectively). 52 
 53 
Supplementary Figure. Co-localization of 53BP1 (green) and γH2AX (red) nuclear 54 
foci in follicular carcinoma (upper and middle panels) and in rat thyroid follicular cells 55 
2 h after 4-Gy irradiation (lower panels), as assessed by double-label 56 
immunofluorescence. The scale bar indicates 20 μm. The scale bar in the inset indicates 57 
2 μm. 58 
 59 
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